Advertisement

Prognostic function of Ki-67 for pathological complete response rate of neoadjuvant chemotherapy in triple-negative breast cancer

Abstract

Aims and background. Triple-negative breast cancer (TNBC) has fluctuating pathological complete response (pCR) rates to neoadjuvant chemotherapy (NAC) according to published reports. Biomarkers predicting pCR rates of NAC would improve TNBC patients’ outcomes. We conducted a meta-analysis to estimate the prognostic function of Ki-67 in relation to pCR rates of NAC in TNBC.
Methods and study design. Relevant publications in the literature from January 2006 to March 2013 were selected by searching PubMed, SpringerLink, Web of Science, Scopus and the Cochrane Library. The quality of prognostic studies was evaluated according to the standard reported by Hayden et al. Relative risk (RR) and 95% confidence interval (CI) were used to estimate the prognostic function of Ki-67 for pCR rates in TNBC. The fail-safe number was used to detect possible publication bias. Review Manager and MIX software was used to merge extracted data.
Results. The pCR rate of TNBC with high Ki-67 expression was 3.36 times that of low Ki-67 expression TNBC. The merged RR was 3.36 (95% CI: 1.61-7.02) and the fail-safe number was 34. No obvious publication bias but heterogeneity of the case series was detected.
Conclusions. Ki-67 was a predictor of pCR rates to NAC in TNBC.

Tumori 2014; 100(2): 136 - 142

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.1700/1491.16395

Authors

Guojing Zhang, Wanqing Xie, Zhaozhe Liu, Chao Lin, Ying Piao, Long Xu, Fang Guo, Xiaodong Xie

Article History

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

  • Zhang, Guojing [PubMed] [Google Scholar]
    Oncology Diagnosis and Treatment Center, The General Hospital of Shenyang Military Region, Shenyang, China
  • Xie, Wanqing [PubMed] [Google Scholar]
    Molecular Biology Laboratory of Traditional Chinese Medicine, The Basic Medical College of Liaoning University of Traditional Chinese Medicine, Shenyang, China
  • Liu, Zhaozhe [PubMed] [Google Scholar]
    Oncology Diagnosis and Treatment Center, The General Hospital of Shenyang Military Region, Shenyang, China
  • Lin, Chao [PubMed] [Google Scholar]
    Department of Gynecology and Obstetrics, Zhejiang Chinese Medical University Affiliated Hospital of Wenzhou Traditional Chinese Medicine, Wenzhou, Zhejiang, China
  • Piao, Ying [PubMed] [Google Scholar]
    Oncology Diagnosis and Treatment Center, The General Hospital of Shenyang Military Region, Shenyang, China
  • Xu, Long [PubMed] [Google Scholar]
    Oncology Diagnosis and Treatment Center, The General Hospital of Shenyang Military Region, Shenyang, China
  • Guo, Fang [PubMed] [Google Scholar]
    Oncology Diagnosis and Treatment Center, The General Hospital of Shenyang Military Region, Shenyang, China
  • Xie, Xiaodong [PubMed] [Google Scholar]
    Oncology Diagnosis and Treatment Center, The General Hospital of Shenyang Military Region, Shenyang, China

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.